• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

The 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, AD/PD™ 2021, will build on the well-earned reputation of the ground-breaking series of Alzheimer’s and Parkinson’s Diseases Conferences, which attract international medical and scientific professionals worldwide.

Transpharmation’s Scientists Caoimhe Tyndall and Teresa Burke will be presenting posters on the topics of “Glial-neuronal interaction prompted by recombinant fibrillar protein constructs of alpha-synuclein – an invitro characterisation” & “A53T alpha-synuclein promotes a rapid neurodegeneration and motor deficit following AAV vector mediated expression in the rat substantia nigra” respectively. Read our abstract papers here: Abstract Papers


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design